• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Dave Silver

Articles by Dave Silver

Panel: Play to strengths, opt for business plans to fit Taiwan conditions

July 25, 2016
By Dave Silver
TAIPEI, Taiwan – At BioBusiness Asia 2016, a two-day conference and part of the four-day BioTaiwan festival, sessions on drug development models and global partnering strategies showcased several Taiwanese companies that have succeeded by adopting strategies tailor-made for Taiwan conditions.
Read More

Taiwan biopharma: Is industry underexplored or just underachieving?

March 30, 2016
By Dave Silver
While debate continues around how much biopharma innovation is actually taking place in Asia, Taiwan is pitching itself as an underexplored location where innovation is available for those who take the time and effort to uncover it.
Read More

New leadership, funding set to boost Taiwan's biopharma industry

March 30, 2016
By Dave Silver
TAIPEI, Taiwan – In recent years, Taiwan has been pouring considerable attention, effort and funding into the development of a sustainable biotech industry, seeking a new economic driver to replace the diminishing prominence of its once-dominant electronics manufacturing sector.
Read More

Taiwan biopharma: Is industry underexplored or just underachieving?

March 30, 2016
By Dave Silver
TAIPEI, Taiwan – While debate continues around how much biopharma innovation is actually taking place in Asia, Taiwan is pitching itself as an underexplored location where innovation is available for those who take the time and effort to uncover it.
Read More

New leadership, funding set to boost Taiwan's biopharma industry

March 29, 2016
By Dave Silver
TAIPEI, Taiwan – In recent years, Taiwan has been pouring considerable attention, effort and funding into the development of a sustainable biotech industry, seeking a new economic driver to replace the diminishing prominence of its once-dominant electronics manufacturing sector.
Read More

OBI Pharma undeterred by market sell-off; forges ahead after phase II/III

March 2, 2016
By Dave Silver
TAIPEI, Taiwan – Taiwan's media and capital markets overlooked the positives from OBI Pharma Inc.'s recently reported top-line results from its global phase II/III trial of the OBI-822/821 active immunotherapy for metastatic breast cancer, which missed its primary endpoints, according to Michael Chang, chairman of the Taipei-headquartered company.
Read More

OBI Pharma undeterred by market sell-off; forges ahead after phase II/III

Feb. 29, 2016
By Dave Silver
TAIPEI, Taiwan – Taiwan's media and capital markets overlooked the positives from OBI Pharma Inc.'s recently reported top-line results from its global phase II/III trial of the OBI-822/821 active immunotherapy for metastatic breast cancer, which missed its primary endpoints, according to Michael Chang, chairman of the Taipei-headquartered company.
Read More

New Zealand is quietly building oncology immunotherapy expertise

Dec. 29, 2015
By Dave Silver

As a small country, New Zealand has always needed to punch above its weight to be noticed, whether in sports, entertainment or science. With its rugby team the All Blacks recent winners of the Rugby World Cup, and the global success of the "Lord of the Rings" and "The Hobbit" film trilogies, there's another area where New Zealand is overachieving considering its population of just 4 million: cancer immunotherapy.


Read More

New Zealand is quietly building oncology immunotherapy expertise

Dec. 29, 2015
By Dave Silver
As a small country, New Zealand has always needed to punch above its weight to be noticed, whether in sports, entertainment or science. With its rugby team the All Blacks recent winners of the Rugby World Cup, and the global success of the "Lord of the Rings" and "The Hobbit" film trilogies, there's another area where New Zealand is overachieving considering its population of just 4 million: cancer immunotherapy.
Read More

Taiwan's OBI Pharma inks deal with Merck for C. diff antibiotic

Oct. 7, 2015
By Dave Silver
TAIPEI, Taiwan – Taipei-based OBI Pharma Inc. has entered a deal with Merck & Co. Inc., of Kenilworth, N.J., for the development and commercialization in Taiwan of its narrow-spectrum macrocyclic antibiotic Dificid (fidaxomicin), which is used to treat Clostridium difficile-associated diarrhea (CDAD). The collaboration represents a long-awaited milestone for OBI as its first major revenue-stream generating deal since its formation in 2002.
Read More
Previous 1 2 3 4 5 6 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe